Patient-Derived Gastric Cancer Assembloids: Integrating Tumor Organoids and Stromal Cell Subpopulations

Study Background and Research Question

Tumor organoid models have become mainstream tools for preclinical cancer research but often fall short in capturing the complex tumor microenvironment, particularly the diverse stromal cell populations that influence disease progression and therapeutic resistance. In gastric cancer—one of the most prevalent and deadly malignancies worldwide—this gap is especially problematic. The five-year survival rate for patients with advanced gastric cancer remains below 10% despite the use of surgery, chemotherapy, and targeted therapies, partly due to pronounced tumor heterogeneity and microenvironment-driven variability in drug response (reference study). The central research question addressed by Shapira-Netanelov et al. is how to construct an in vitro tumor model that more faithfully recapitulates the cellular and stromal complexity of patient tumors, thereby enabling more predictive studies of drug response and resistance mechanisms.

Key Innovation from the Reference Study

The primary innovation described in the 2025 study is the development of a patient-specific gastric cancer assembloid model that integrates matched tumor organoids with autologous stromal cell subpopulations—including mesenchymal stem cells, fibroblasts, and endothelial cells—derived from the same tumor tissue. Unlike conventional organoid monocultures, these assembloids establish a co-culture system that mirrors the heterogeneity and cellular interactions present in primary tumors. This approach offers enhanced physiological relevance, allowing for more accurate modeling of gene expression, cell–cell signaling, and drug response heterogeneity. Notably, the inclusion of patient-matched stromal populations provides a platform to dissect how stromal diversity shapes biomarkers, transcriptomic profiles, and therapeutic outcomes.

Methods and Experimental Design Insights

The protocol begins with the dissociation of resected gastric tumor tissue, followed by the expansion of epithelial tumor cells and distinct stromal cell types in tailored growth media. Tumor organoids are cultured using established protocols, while mesenchymal, fibroblast, and endothelial lineages are isolated and expanded in parallel. These populations are then recombined in an optimized assembloid medium that supports the viability and function of each cell type, allowing the formation of multicellular structures that recapitulate the cellular composition and architecture of the originating tumor. Key methods include:

• Immunofluorescence staining to confirm the presence and phenotype of both epithelial and stromal cell types within the assembloids.
• RNA sequencing to profile global transcriptomic changes and compare gene expression patterns between monocultures and assembloids.
• Cell viability and drug sensitivity assays, exposing both organoid and assembloid models to a panel of therapeutic agents to evaluate differences in response.

This multi-modal characterization enables high-resolution analysis of how stromal composition modulates tumor biology and pharmacological response.

Protocol Parameters

• Tissue dissociation: Mechanically and enzymatically dissociate fresh gastric tumor tissue immediately post-resection to maximize cell viability and preserve stromal diversity.
• Cell expansion: Culture epithelial, mesenchymal, fibroblast, and endothelial populations in lineage-specific media to enrich subpopulations before assembloid assembly.
• Assembloid formation: Combine organoids and stromal subtypes in optimized co-culture media, typically at ratios reflecting the histological features of the original tumor.
• Immunofluorescence and transcriptomics: Use established protocols for biomarker staining and RNA-seq library preparation to characterize cellular composition and gene expression.
• Drug screening: Assess drug response using cell viability assays (e.g., ATP-based luminescence or resazurin reduction) after defined treatment intervals, comparing monoculture and assembloid outcomes.

Core Findings and Why They Matter

The optimized assembloid models faithfully recapitulate the cellular heterogeneity and microenvironmental cues observed in primary gastric tumors. Immunofluorescence confirmed the coexistence of epithelial and multiple stromal populations, while transcriptomic analysis revealed that assembloids exhibit higher expression of inflammatory cytokines, extracellular matrix remodeling factors, and tumor progression-associated genes than organoid monocultures. Critically, drug screening highlighted that stromal inclusion alters therapeutic responses: certain agents lost efficacy in the assembloid context, underscoring the importance of tumor–stroma interactions in mediating drug resistance (reference study). These findings establish the assembloid system as a robust preclinical platform for dissecting tumor–stroma crosstalk, identifying resistance mechanisms, and optimizing personalized treatment strategies. The model supports the study of oncogenic kinase signaling pathways, biomarker discovery, and rational drug combination testing in a physiologically relevant context.

Comparison with Existing Internal Articles and Broader Context

Recent internal literature, such as the scenario-driven guidance on Crizotinib hydrochloride deployment in assembloid models, echoes the importance of physiologically relevant in vitro systems for kinase inhibitor studies. As discussed in the article "Crizotinib Hydrochloride in the Era of Tumor Assembloids" (read more), integrating kinase inhibitors into assembloid workflows enables researchers to probe the inhibition of ALK and c-Met phosphorylation under microenvironmental influences, closely paralleling the experimental rationale of the reference gastric cancer study. The assembloid-focused article further contextualizes how this model system enables more predictive drug response profiling and insight into resistance mechanisms, providing a bridge between fundamental cancer biology research and translational applications.

Limitations and Transferability

While the assembloid model offers significant advances in recapitulating tumor-stroma complexity, several limitations merit consideration. First, the technical demands of isolating and maintaining multiple autologous cell lineages from limited patient tissue may restrict scalability for high-throughput screening. Second, in vitro assembloids, despite their complexity, cannot fully reproduce systemic factors (e.g., immune cell infiltration, vascular perfusion) present in vivo. Finally, the reference study's focus on gastric cancer means that transferability to other tumor types will require tailored optimization of cell isolation and culture protocols, as well as careful validation of stromal composition and functional endpoints.

Research Support Resources

Researchers seeking to model oncogenic kinase signaling pathways or screen for resistance mechanisms in complex tumor environments can leverage reagents such as Crizotinib hydrochloride (SKU B3608). As an orally bioavailable ALK kinase inhibitor with potent inhibition of ALK and c-Met phosphorylation, Crizotinib hydrochloride supports studies of ALK or ROS1-driven signaling pathways in assembloid models and other advanced cancer biology research applications. The compound's high purity and solubility profiles, as detailed by APExBIO, facilitate reproducible interrogation of oncogenic kinase pathways in cell-based assays. For more scenario-driven workflow guidance, researchers may also consult the internal article for best practices in kinase inhibitor deployment in assembloid-based studies.